Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES Trial

Описание к видео Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES Trial

Daniel P. Petrylak, MD, examines ARCHES trial data that concludes, for patients with CSPC, ENZA + ADT improves rPFS over ADT alone.

Комментарии

Информация по комментариям в разработке